辅助曲妥珠单抗美坦新(T-DM1)对比紫杉醇联合曲妥珠单抗治疗I期人表皮生长因子受体2阳性乳腺癌:ATEMPT研究的5年结果与相关性分析
ATEMPT II期试验将I期中心确认HER2阳性乳腺癌患者按3:1随机分配接受辅助T-DM1治疗1年或紫杉醇联合曲妥珠单抗(TH)治疗。中位随访5.8年,T-DM1组5年iDFS为97.0%,TH组为91.1%(原文说明该终点未设统计效能);HER2DX低风险较高风险肿瘤患者RFI和iDFS更优。
要点
- 中位随访5.8年,T-DM1组5年iDFS为97.0%(95% CI 95.2至98.7),TH组为91.1%(原文说明该终点未设统计效能)。
- T-DM1组5年RFI为98.3%、OS为97.8%、BCSS为99.4%。
- HER2DX低风险较高风险肿瘤患者RFI(98.1% vs 81.8%,HR 0.10,P=0.01)和iDFS(96.3% vs 81.8%,HR 0.20,P=0.047)更优。
核心结论
- 辅助T-DM1治疗1年为I期HER2阳性乳腺癌患者带来优异的长期结局。
- HER2DX高风险评分预测ATEMPT研究中更高的复发风险。
研究设计与样本
- ATEMPT为II期试验,将I期中心确认HER2阳性乳腺癌患者按3:1随机分配接受辅助T-DM1治疗1年或紫杉醇联合曲妥珠单抗(TH)治疗。
- 共同主要目标为比较两臂临床相关毒性发生率及评估T-DM1的无侵袭性疾病生存(iDFS)。
- 相关性分析包括HER2DX基因组工具、HER2异质性多组学评估及血小板减少预测因素。
主要发现
- 中位随访5.8年,T-DM1组观察到11例iDFS事件,5年iDFS为97.0%(95% CI 95.2至98.7)。
- 5年时,T-DM1组RFI为98.3%(95% CI 97.0至99.7),OS为97.8%(95% CI 96.3至99.3),BCSS为99.4%(95% CI 98.6至100)。
- 无论肿瘤大小、激素受体状态、中心判定HER2免疫组化评分及接受T-DM1超过或不足6个月,T-DM1组iDFS相当。
- ATEMPT未针对该终点设统计效能,TH组5年iDFS为91.1%。
- 在具有足够组织进行HER2DX检测的患者(n=187)中,HER2DX低风险较高风险肿瘤患者RFI更优(98.1% vs 81.8%,HR 0.10,P=0.01),iDFS更优(96.3% vs 81.8%,HR 0.20,P=0.047)。
关键数值与推荐
- T-DM1组5年iDFS为97.0%(95% CI 95.2至98.7),TH组5年iDFS为91.1%(原文说明未设统计效能)。
- T-DM1组5年RFI为98.3%(95% CI 97.0至99.7),OS为97.8%(95% CI 96.3至99.3),BCSS为99.4%(95% CI 98.6至100)。
- HER2DX低风险较高风险肿瘤患者RFI为98.1% vs 81.8%(HR 0.10,P=0.01),iDFS为96.3% vs 81.8%(HR 0.20,P=0.047)。
临床怎么用
- 辅助T-DM1治疗1年可为I期HER2阳性乳腺癌患者带来优异的长期结局。
- HER2DX高风险评分预测更高的复发风险。
局限性
- ATEMPT未针对TH臂iDFS比较设统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need. METHODS: In the ATEMPT phase II trial, patients with stage I centrally confirmed HER2-positive breast cancer were randomly assigned 3:1 to adjuvant T-DM1 for 1 year or paclitaxel plus trastuzumab (TH). Coprimary objectives were to compare the incidence of clinically relevant toxicities between arms and to evaluate invasive disease-free survival (iDFS) with T-DM1. Correlative analyses included the HER2DX genomic tool, multiomic evaluations of HER2 heterogeneity, and predictors of thrombocytopenia. RESULTS: After a median follow-up of 5.8 years, 11 iDFS events were observed in the T-DM1 arm, consistent with a 5-year iDFS of 97.0% (95% CI, 95.2 to 98.7). At 5 years, the recurrence-free interval (RFI) was 98.3% (95% CI, 97.0 to 99.7), the overall survival was 97.8% (95% CI, 96.3 to 99.3), and the breast cancer-specific survival was 99.4% (95% CI, 98.6 to 100). Comparable iDFS was observed with T-DM1 irrespective of tumor size, hormone receptor status, centrally determined HER2 immunohistochemical score, and receipt of T-DM1 for more or less than 6 months. Although ATEMPT was not powered for this end point, the 5-year iDFS in the TH arm was 91.1%. Among patients with sufficient tissue for HER2DX testing (n = 187), 5-year outcomes significantly differed according to HER2DX risk score, with better RFI (98.1% v 81.8%, hazard ratio [HR], 0.10, P = .01) and iDFS (96.3% v 81.8%, HR, 0.20, P = .047) among patients with HER2DX low-risk versus high-risk tumors, respectively. CONCLUSION: Adjuvant T-DM1 for 1 year leads to outstanding long-term outcomes for patients with stage I HER2-positive breast cancer. A high HER2DX risk score predicted a higher risk of recurrence in ATEMPT.
引用
- Tarantino P, Tayob N, Villacampa G, et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024. PMID: 38935923. doi:10.1200/JCO.23.02170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。